GALMED PHARMACEUTICALS LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3976 USD | -1.83% |
|
+2.40% | -12.62% |
Presentation Operator MessageOperator (Operator)Good day. Welcome to the Galmed conference cal...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).
Calendar
2025-05-06
- Q1 2025 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.405
USD
Average target price
1
USD
Spread / Average Target
+146.91%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.62% | 2.43M | |
| +9.58% | 115B | |
| +12.41% | 106B | |
| -2.59% | 21.96B | |
| -12.38% | 21.87B | |
| -5.29% | 19.21B | |
| -3.35% | 18.08B | |
| -38.57% | 17.71B | |
| +7.51% | 14.32B | |
| +35.67% | 12.42B |
- Stock Market
- Equities
- GLMD Stock
- News Galmed Pharmaceuticals Ltd.
- Transcript : Galmed Pharmaceuticals Ltd., Q1 2020 Earnings Call, May 14, 2020